A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1 | Zendy

Michael S. Saag | Zendy; James Goodrich | Zendy; Gerd Fätkenheuer | Zendy; Bonaventura Clotet | Zendy; Nathan Clumeck | Zendy; John F. Sullivan | Zendy; Mike Westby | Zendy; Elna van der Ryst | Zendy; Howard Mayer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1

Author(s) -

Michael S. Saag,

James Goodrich,

Gerd Fätkenheuer,

Bonaventura Clotet,

Nathan Clumeck,

John F. Sullivan,

Mike Westby,

Elna van der Ryst,

Howard Mayer

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/598965

Subject(s) - maraviroc , ccr5 receptor antagonist , medicine , placebo , viral load , adverse effect , randomized controlled trial , clinical endpoint , lentivirus , human immunodeficiency virus (hiv) , immunology , gastroenterology , viral disease , receptor , pathology , chemokine , alternative medicine , chemokine receptor

Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in treatment-experienced patients infected with dual- or mixed-tropic HIV-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research